Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation.

Xenotransplantation
Nora SchwotzerManuel Pascual

Abstract

Acute antibody-mediated rejection (AMR) early after transplant remains a challenge, both in allotransplantation and in xenotransplantation. We report the case of an early and severe acute AMR episode in a kidney transplant recipient that was successfully treated with upfront eculizumab. A 58-year-old woman had been on dialysis since 2014. She underwent a first kidney transplant in 2018 with primary non-function and received several blood transfusions. Postoperatively, she developed anti-HLA antibodies. One year later, she received a second allograft from a deceased donor. At day 0, there was only one preformed low-level donor-specific antibody (DSA) anti-DQ7. After initial excellent allograft function, serum creatinine increased on days 7-9, and this was associated with oligo-anuria. On day 7, there was an increase in her DSA anti-DQ7 and 4 de novo DSA had developed at high MFI values. Allograft biopsy showed severe active AMR with diffuse C4d deposits in peritubular capillaries. The early acute AMR episode was treated with upfront eculizumab administration (2 doses) with efficient CH50 blockade (< 10% CH50). Rituximab was also administered on day 12, and intravenous immunoglobulin (IVIG) was given over the following days. Ther...Continue Reading

References

Nov 18, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·G A BöhmigW Druml
Mar 30, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·J E LockeR A Montgomery
Sep 20, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hao WangRussell P Rother
Nov 4, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·J E LockeR A Montgomery
Nov 4, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·J M BurnsM D Stegall
Sep 29, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M D StegallJ M Gloor
Mar 4, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·L D CornellM D Stegall
Oct 20, 2015·Transplantation·Hassib Chehade, Manuel Pascual
Oct 28, 2018·Nature Reviews. Nephrology·Ali-Reza BiglarniaBo Nilsson
Mar 20, 2019·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·William H MarksUNKNOWN C10-001 Study Group
Apr 24, 2019·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Denis GlotzUNKNOWN C10-002 Study Group
May 21, 2020·Transplantation·Joseph M LadowskiDavid K C Cooper

❮ Previous
Next ❯

Citations

Oct 7, 2020·Xenotransplantation·Yoshihide Nanno, Christopher Burlak
Mar 25, 2021·Xenotransplantation·Raphael P H MeierManuel Pascual

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.